Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03295981 · ClinicalTrials.gov registry record · Phase 3
Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone
A Phase 3 study of Giant Cell Tumor of Bone, sponsored by St. Louis University.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 120
- Enrollment target
- 16
- Study locations
NCT03295981: Recruiting Phase 3 study of Giant Cell Tumor of Bone, sponsored by St. Louis University.
NCT03295981 is a Phase 3 study of Giant Cell Tumor of Bone that is actively recruiting participants, run by St. Louis University. The registered enrollment target is 120 participants, below the 305-participant average among 3 other Giant Cell Tumor of Bone trials with a reported enrollment target (61% lower). The trial reports 16 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03295981, a Phase 3 study of Giant Cell Tumor of Bone, is actively recruiting participants, sponsored by St. Louis University.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 120 participants
- Enrollment target
- 16
- Study locations
Study Summary
The purpose of the clinical study is to investigate whether the local delivery of bisphosphonate as a surgical adjuvant can decrease the chance of a giant cell tumor of bone coming back to the same location. The hypothesis is that the local administration of bisphosphonate will decrease the rate of the tumor returning compared to traditional aggressive surgical removal of the tumor.
Primary Outcome
Local recurrence of giant cell tumor of bone
Conditions Studied
Interventions
- DRUG Zoledronic Acid
Study Locations (16)
Massachusetts
- Massachusetts General Hospital - Boston
- Boston Children's Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
California
- University of California - Los Angeles - Los Angeles
Indiana
- Indiana University - Indianapolis
Iowa
- University of Iowa - Iowa City
Kansas
- University of Kansas - Overland Park
Maryland
- Johns Hopkins University Hospital - Baltimore
Missouri
- Saint Louis University - St Louis
North Carolina
- Wake Forest University - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2018-05-03 |
| Est. Completion | 2028-01 |
| Phase | Phase 3 |
What NCT03295981 shows while recruiting
NCT03295981 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 305-participant average among 3 other Giant Cell Tumor of Bone trials with a reported enrollment target (61% lower).
The record links to 1 condition, with Giant Cell Tumor of Bone appearing as the primary indexed condition, and to 1 intervention - of which Zoledronic Acid is the first listed.
NCT03295981 lists 16 locations in 14 states (Massachusetts, California, Indiana).
Frequently Asked Questions
What is clinical trial NCT03295981 about?
NCT03295981 is a clinical study titled "Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone". The purpose of the clinical study is to investigate whether the local delivery of bisphosphonate as a surgical adjuvant can decrease the chance of a giant cell tumor of bone coming back to the same location. The hypothesis is that the local administration of bisphosphonate will decrease the rate of ...
What is the current status of trial NCT03295981?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 120 participants. The study started on 2018-05-03. Estimated completion is 2028-01.
What conditions does trial NCT03295981 study?
This clinical trial studies the following conditions: Giant Cell Tumor of Bone.
What interventions are being tested in trial NCT03295981?
The interventions under investigation include: Zoledronic Acid (DRUG).
Who is sponsoring clinical trial NCT03295981?
This trial is sponsored by St. Louis University, which has 107 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03295981 being conducted?
This trial has 16 study locations across California, Indiana, Iowa, Kansas, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Giant Cell Tumor of Bone
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PROMIS and Mobility Evaluation in Sarcoma Patients
RECRUITING
-
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
ACTIVE NOT RECRUITING · Phase 2
-
Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI